Coriolis Pharma’s in silico developability assessment helps to identify lead candidates with the highest success potential while defining formulation-relevant parameters. This method enables early detection of critical risks, including colloidal and conformational instability, aggregation, high viscosity, and chemical degradation pathways such as oxidation and deamidation—all without the need for physical material.